Cello Health : Board Changes

16th August 2018

Cello Health plc (AIM: CLL), the global healthcare-focused advisory Group, is pleased to announce the appointment, with immediate effect,of two independent non-executive directors to the Company's board of directors (the 'Board'). The new Board members, Clifford Tompsett and Jo LeCouilliard, both have extensive experience in the pharmaceutical industry.

Clifford Tompsettwas until recently a senior partnerat PriceWaterhouseCoopers LLP ('PwC'),with responsibility for the firm's global cross border IPO practice. For a number of years Clifford led the firm's UK and European activitiesin the pharmaceutical sector, advising onmany of the large deals in theindustry. He was at PwCfor 38 years, and is a qualified chartered accountant. Clifford will head the Board's Audit Committee and he will also be theCompany'sSenior Independent Director.

Jo LeCouilliard wasuntil recently at GlaxoSmithKline plc where she held senior executive positions globally with roles in regions including the United Statesand Asia. Johas also heldsenior hospital management positions at BMI Healthcare,andis currentlya non-executive director ofCircassia Pharmaceuticals plc.

In line with the plans announced at the Annual General Meetingon 10May 2018, Paul Hamilton and Will David have both stood down as non-executive directors with immediate effect, each having servedas members of the Board for more thana decade.

Mark Scott, CEO of Cello,said:

'Both Paul Hamilton and Will David have been non-executive directors of the Companysince its formation. Throughout that time, they have helped the Board shape the Group into a leading internationalbusiness serving predominantlyhealth orientated clients. We are profoundly grateful for their efforts, and wish them both the best for the future.

'I am delighted that the Group has securedthe services of two, highlyexperienced and capable new non-executive directors with deep experience across the pharmaceutical industry. The Board very much looksforward to working with Clifford and Jo as we shape the future growth path for the Group.'

Regulatory information

Mr. Tompsett and Ms. LeCouilliard do not have any interests in the ordinary shares of the Company.

There are no further disclosures to be made pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of the appointments of Mr. Tompsett and Ms. LeCouilliard.